Welcome to our dedicated page for Celcuity news (Ticker: CELC), a resource for investors and traders seeking the latest updates and insights on Celcuity stock.
Celcuity Inc (CELC) delivers innovative oncology solutions through its integrated approach combining advanced cellular diagnostics with targeted therapeutic development. This dedicated news hub provides investors and researchers with essential updates on clinical milestones, regulatory developments, and strategic partnerships.
Access authoritative information about Celcuity's Phase 3 trials for gedatolisib in advanced breast cancer, progress in prostate cancer research, and advancements in their CELsignia companion diagnostic platform. Our curated collection includes press releases about trial enrollments, partnership announcements with pharmaceutical leaders, and financial disclosures critical for market analysis.
Key updates cover therapeutic pipeline progress, diagnostic technology enhancements, and scientific presentations at major oncology conferences. The resource serves both expert analysts and general investors seeking to understand Celcuity's position in precision medicine.
Bookmark this page for real-time access to verified CELC developments. For comprehensive tracking of this clinical-stage biotech leader's progress in personalized cancer treatment, revisit regularly as new information becomes available.
Celcuity Inc. (Nasdaq:CELC) recently presented preclinical studies on gedatolisib, a pan-PI3K and mTOR inhibitor, showcasing its enhanced anti-tumor efficacy in gynecological cancer models, including endometrial, ovarian, and cervical cancers. The data, revealed at the 2023 AACR Annual Meeting, indicate gedatolisib outperformed other PAM inhibitors irrespective of mutational status, demonstrating significant tumor growth inhibition in vivo. The findings suggest gedatolisib's potential across various solid tumors, reinforcing its differentiated mechanism of action. Currently, a Phase 3 trial, VIKTORIA-1, is ongoing to further evaluate gedatolisib's effectiveness in treating HR+/HER2- advanced breast cancer. These developments highlight the investigational drug's promising profile and potential market impact in oncology.
FAQ
What is the current stock price of Celcuity (CELC)?
What is the market cap of Celcuity (CELC)?
